BLACK DIAMOND THERAPEUTICS I (BDTX)
US09203E1055 - Common Stock
Taking everything into account, BDTX scores 2 out of 10 in our fundamental rating. BDTX was compared to 568 industry peers in the Biotechnology industry. While BDTX seems to be doing ok healthwise, there are quite some concerns on its profitability. BDTX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BDTX has reported negative net income.
BDTX had a negative operating cash flow in the past year.
BDTX had negative earnings in each of the past 5 years.
In the past 5 years BDTX always reported negative operating cash flow.
1.2 Ratios
BDTX has a Return On Assets (-53.01%) which is in line with its industry peers.
With a Return On Equity value of -75.03%, BDTX perfoms like the industry average, outperforming 55.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.01% | ||
| ROE | -75.03% | ||
| ROIC | N/A |
ROA(3y)-53.68%
ROA(5y)-40.74%
ROE(3y)-71.18%
ROE(5y)-51.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BDTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, BDTX has more shares outstanding
BDTX has more shares outstanding than it did 5 years ago.
BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
BDTX has an Altman-Z score of -4.07. This is a bad value and indicates that BDTX is not financially healthy and even has some risk of bankruptcy.
BDTX's Altman-Z score of -4.07 is in line compared to the rest of the industry. BDTX outperforms 41.59% of its industry peers.
There is no outstanding debt for BDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.07 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 5.55 indicates that BDTX has no problem at all paying its short term obligations.
BDTX's Current ratio of 5.55 is in line compared to the rest of the industry. BDTX outperforms 58.58% of its industry peers.
A Quick Ratio of 5.55 indicates that BDTX has no problem at all paying its short term obligations.
The Quick ratio of BDTX (5.55) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.55 | ||
| Quick Ratio | 5.55 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 37.56% over the past year.
EPS 1Y (TTM)37.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 9.11% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.47%
EPS Next 2Y15.61%
EPS Next 3Y5.67%
EPS Next 5Y9.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BDTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.61%
EPS Next 3Y5.67%
5. Dividend
5.1 Amount
No dividends for BDTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BLACK DIAMOND THERAPEUTICS I
NASDAQ:BDTX (12/20/2024, 8:00:01 PM)
After market: 2.2599 +0.04 (+1.8%)2.22
+0.03 (+1.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.15%
Inst Owner Change2.62%
Ins Owners0.37%
Ins Owner Change0.11%
Market Cap125.63M
Analysts86.15
Price Target14.79 (566.22%)
Short Float %11.09%
Short Ratio10.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.7%
Min EPS beat(2)8.83%
Max EPS beat(2)26.57%
EPS beat(4)4
Avg EPS beat(4)21.25%
Min EPS beat(4)8.83%
Max EPS beat(4)28.47%
EPS beat(8)8
Avg EPS beat(8)14.38%
EPS beat(12)12
Avg EPS beat(12)14.36%
EPS beat(16)14
Avg EPS beat(16)9.06%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.25%
PT rev (3m)4.82%
EPS NQ rev (1m)2.65%
EPS NQ rev (3m)14.17%
EPS NY rev (1m)1.94%
EPS NY rev (3m)7.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.29 | ||
| P/tB | 1.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.33
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS1.72
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.01% | ||
| ROE | -75.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-53.68%
ROA(5y)-40.74%
ROE(3y)-71.18%
ROE(5y)-51.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.55 | ||
| Quick Ratio | 5.55 | ||
| Altman-Z | -4.07 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)445.09%
Cap/Depr(5y)331.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
EPS Next Y29.47%
EPS Next 2Y15.61%
EPS Next 3Y5.67%
EPS Next 5Y9.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.02%
EBIT Next 3Y4.72%
EBIT Next 5Y4.61%
FCF growth 1Y30.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.8%
OCF growth 3YN/A
OCF growth 5YN/A